Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Pinelopi Vryttia
Observed names:
P. Vryttia,
Pinelopi Vrytia
Institutions:
National and Kapodistrian University of Athens,
University General Hospital Attikon
Observed institutions:
National and Kapodistrian University of Athens,
Alexandra Hospital,
University General Hospital Attikon
ORCID:
0009-0000-9892-8787
Observed ORCID:
0009-0000-9892-8787
OpenAlex ID:
A5034912998
Nocebo-Prone Behavior Associated with SARS-CoV-2 Vaccine Hesitancy in Healthcare Workers
2021
·
Dimos D. Mitsikostas
, Konstantina Aravantinou-Fatorou
, et al.
·
Vaccines
·
14
PDF
Real-Life Multicenter Experience of Venetoclax in Combination with Hypomethylating Agents in Previously Untreated Adult Patients with Acute Myeloid Leukemia in Greece
2024
·
Theodora Chatzilygeroudi
, Ismini Darmani
, et al.
·
Journal of Clinical Medicine
·
6
PDF
Role of Complement Anaphylatoxins (C3a and C5a) in Lymphoma: A Systematic Review
2025
·
Konstantinos Skarentzos
, Pinelopi Vryttia
, et al.
·
Cureus
·
2
PDF
Prognostic Role of Adaptive Immune Microenvironment in Patients with High-Risk Myelodysplastic Syndromes Treated with 5-Azacytidine
2025
·
Zoi Tsakiraki
, Aris Spathis
, et al.
·
Cancers
·
1
The Role of 24‐Month Progression‐Free Survival (PFS24) in the Long‐Term Evaluation of Patients With Diffuse Large B Cell Lymphoma (DLBCL): A Real‐World Single Center Study
2025
·
Pinelopi Vryttia
, Anthi Bouchla
, et al.
·
Hematological Oncology
·
1
The Prognostic Significance of Serum β2- Microglobulin Levels (sβ2m) in Diffuse Large B-Cell Lymphoma (DLBCL)
2024
·
Maria Panagiota Arapaki
, Evgenia Verrou
, et al.
·
Blood
·
1
PDF
Low Dose Post-Transplant Cyclophosphamide in Combination with Alemtuzumab As Gvhd-Prophylaxis Is Associated with Improved Outcomes and Safe Side Effect Profile in HLA-Mismatched Unrelated Transplantation
2024
·
Panagiotis Tsirigotis
, Ioanna Lazana
, et al.
·
Blood
·
1
PDF
Myelodysplastic Syndrome Red Blood Cell Physiology Abnormalities and Their Correlation with Disease Risk and Therapeutic Interventions
2023
·
Pinelopi Vryttia
, Konstantina Theocharaki
, et al.
·
Blood
·
1
Real-world effectiveness and safety of ropeginterferon alfa-2b in polycythemia vera: a competing-risk analysis
2026
·
Thomas P. Thomopoulos
, Anthi Bouchla
, et al.
·
Annals of Hematology
Beyond Extranodal Site Count: Clinical and Anatomical Characterization of Primary Multifocal Extranodal Diffuse Large B‐Cell Lymphoma
2026
·
Thomas P. Thomopoulos
, Christina Apostolopoulou
, et al.
·
European Journal Of Haematology
PDF
Red cell phenotypes and associations with disease severity in low-risk myelodysplastic syndromes
2026
·
Pinelopi Vryttia
, Konstantina Theocharaki
, et al.
·
Blood Red Cells & Iron
PDF
PPPR15A, a stress response gene is upregulated in malignant myeloid progenitors in AML and higher risk MDS.
2025
·
Agni Vitsioti
, Konstantinos Theodorakopoulos
, et al.
·
Blood
Mds Biology and Pathogenesis - Immune Deregulation / Inflammation
2025
·
Pinelopi Vryttia
, Konstantina Theocharaki
, et al.
·
Leukemia Research
Author response for "The Role of 24‐Month Progression‐Free Survival (PFS24) in the Long‐Term Evaluation of Patients With Diffuse Large B Cell Lymphoma (DLBCL): A Real‐World Single Center Study"
2024
·
Pinelopi Vryttia
, Anthi Bouchla
, et al.
·
Publons reviews and discussion
High Incidence of Thalassemia Traits Among Myelodysplastic Syndrome Patients May Mask Macrocytic Anemia but Not the Enhanced Proteasome Proteolytic Activity
2024
·
Pinelopi Vryttia
, Konstantina Theoharaki
, et al.
·
Blood
PDF
Pb1740: the Combination of Ponatinib Plus Chemotherapy Upfront Achieves Durable Complete Molecular Remissions in Adults Patients With Philadelphia Chromosome-positive (ph+) Acute Lymphoblastic Leukemia.
2023
·
Papageorgiou Sotirios
, Anthi Bouchla
, et al.
·
HemaSphere
Topic: AS08-Treatment/AS08b-Current treatment options – Lower risk MDS: LUSPATERCEPT IN THE TREATMENT OF MDS PATIENTS. A SINGLE CENTER EXPERIENCE
2023
·
A. Bouchla
, T. Thomopoulos
, et al.
·
Leukemia Research
Show more works
View as search
Works count:
17
Citation count:
27
H-index:
2
I10-index:
1
Year
Topic
Type